EP3997128A4 - Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern - Google Patents
Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern Download PDFInfo
- Publication number
- EP3997128A4 EP3997128A4 EP20836912.4A EP20836912A EP3997128A4 EP 3997128 A4 EP3997128 A4 EP 3997128A4 EP 20836912 A EP20836912 A EP 20836912A EP 3997128 A4 EP3997128 A4 EP 3997128A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hsc
- patient
- hematopoietic
- stem cells
- specific antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003394 haemopoietic effect Effects 0.000 title 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/506,764 US11104738B2 (en) | 2016-04-04 | 2019-07-09 | Monoclonal antibodies to human FLT3/FLK2 receptor protein |
PCT/US2020/041095 WO2021007266A1 (en) | 2019-07-09 | 2020-07-08 | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3997128A1 EP3997128A1 (de) | 2022-05-18 |
EP3997128A4 true EP3997128A4 (de) | 2023-10-18 |
Family
ID=74115143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20836912.4A Withdrawn EP3997128A4 (de) | 2019-07-09 | 2020-07-08 | Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3997128A4 (de) |
JP (1) | JP2022540602A (de) |
CN (1) | CN114829399A (de) |
CA (1) | CA3146912A1 (de) |
WO (1) | WO2021007266A1 (de) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017219025A1 (en) * | 2016-06-17 | 2017-12-21 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
US20180110832A1 (en) * | 2015-04-20 | 2018-04-26 | The Board Of Regents Of The University Of Texas Sy Stem | Clec11a is a bone growth agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2732925C2 (ru) * | 2015-01-26 | 2020-09-24 | Селлектис | МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК |
CA3019581A1 (en) * | 2016-04-04 | 2017-10-12 | Hemogenyx Llc | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
US20200048618A1 (en) * | 2017-04-18 | 2020-02-13 | Autolus Limited | Cell |
-
2020
- 2020-07-08 EP EP20836912.4A patent/EP3997128A4/de not_active Withdrawn
- 2020-07-08 WO PCT/US2020/041095 patent/WO2021007266A1/en unknown
- 2020-07-08 CN CN202080062829.8A patent/CN114829399A/zh active Pending
- 2020-07-08 CA CA3146912A patent/CA3146912A1/en active Pending
- 2020-07-08 JP JP2022501020A patent/JP2022540602A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180110832A1 (en) * | 2015-04-20 | 2018-04-26 | The Board Of Regents Of The University Of Texas Sy Stem | Clec11a is a bone growth agent |
WO2017219025A1 (en) * | 2016-06-17 | 2017-12-21 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
Also Published As
Publication number | Publication date |
---|---|
CN114829399A (zh) | 2022-07-29 |
CA3146912A1 (en) | 2021-01-14 |
WO2021007266A1 (en) | 2021-01-14 |
JP2022540602A (ja) | 2022-09-16 |
EP3997128A1 (de) | 2022-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3439699A4 (de) | Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern | |
EP3924375A4 (de) | Universalspenderstammzellen und zugehörige verfahren | |
EP3914271A4 (de) | Zusammensetzungen und verfahren zur erzeugung von hämatopoetischen stammzellen (hscs) | |
EP4130286A4 (de) | Verfahren zur deamidierung von proteinen | |
EP4029947A4 (de) | Verfahren zur herstellung von pflanzenproteinkonzentrat | |
EP3980465A4 (de) | Gentechnisch veränderte ph-abhängige anti-cd3-antikörper und verfahren zu deren herstellung und verwendung | |
EP3969560A4 (de) | Mikrofluidische vorrichtung und verfahren zur verwendung zur zellzüchtung | |
EP3980067A4 (de) | Antikörper-interleukin-fusionsprotein und anwendungsverfahren | |
EP4089822A4 (de) | Lithiumnachfüllende membran und verfahren zur herstellung der lithiumnachfüllenden membran | |
EP4051478A4 (de) | Simuliertes chirurgisches system, simuliertes gefäss und verfahren zu dessen herstellung und zugehörige komponenten | |
EP4028525A4 (de) | Kombinierte expression eines chimären cd3 fusionsproteins und eines bispezifischen t-zell-aktivierenden elements auf der basis von anti-cd3 | |
EP3970744A4 (de) | Stabile secukinumabinjektion und verfahren zu ihrer herstellung | |
EP3973048A4 (de) | Zusammensetzungen und verfahren zur pflanzenzellzüchtung | |
EP3831926A4 (de) | Zellkultursystem und verfahren zur zellmassenproduktion damit | |
EP4069298A4 (de) | Zusammensetzung von triaxialen antikörpern und verfahren zu ihrer herstellung und verwendung | |
EP4022041A4 (de) | Nef-haltige t-zellen und verfahren zum produzieren davon | |
EP3976066A4 (de) | Verfahren zur erzeugung und expansion von hämatopoetischen stammzellen | |
EP3959996A4 (de) | Emulsionszusammensetzung mit saatspeicherprotein und verfahren zu deren herstellung | |
EP3997128A4 (de) | Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern | |
EP4051777A4 (de) | Verfahren und vorrichtung für muldenplatten für die zellkultur | |
EP4110900A4 (de) | Erzeugung von aorta-gonaden-mesonephros-ähnlichen hämatopoetischen zellen aus humanen pluripotenten stammzellen unter einem definierten zustand | |
EP4065232A4 (de) | Anti-cd3-scfv und zytokin produzierende künstliche antigenpräsentierende zellen | |
EP3985103A4 (de) | Zellen mit fähigkeit zur differenzierung in plazentakonstituierende zellen und verfahren zu ihrer herstellung | |
EP4074819A4 (de) | Verfahren zur herstellung von mesenchymalen stammzellen aus menschlichen pluripotenten stammzellen und dadurch hergestellte mesenchymale stammzellen | |
EP3979360A4 (de) | Feststoffbatterie und verfahren zur herstellung davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220114 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101ALI20230606BHEP Ipc: A61P 37/06 20060101ALI20230606BHEP Ipc: A61K 45/06 20060101ALI20230606BHEP Ipc: A61K 39/395 20060101ALI20230606BHEP Ipc: C07K 16/28 20060101AFI20230606BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230914 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101ALI20230908BHEP Ipc: A61P 37/06 20060101ALI20230908BHEP Ipc: A61K 45/06 20060101ALI20230908BHEP Ipc: A61K 39/395 20060101ALI20230908BHEP Ipc: C07K 16/28 20060101AFI20230908BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20240219 |